We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Antimitochondrial antibody serocoversion post-liver transplant during hepatitis C treatment with peginterferon α, ribavirin and telaprevir.
- Authors
Marquez-Azalgara, Vladimir; Hussaini, Trana; Erb, Siegfried R.; Yoshida, Eric M.
- Abstract
Pegylated interferon alpha (PEG-IFN α), a key component of chronic hepatitis C therapy, has been linked to the development of auto-antibodies and autoimmune disease. We report the first case of antimitochondrial antibody (AMA) seroconversion during PEG-INF α based therapy after liver.1-4 transplantation. A fiftyseven year-old man five months after liver transplantation was initiated on hepatitis C triple therapy with PEG-INF α, ribavirin and telaprevir. He had failed previous PEG-IFN α and ribavirin 12 years pre-transplant and his AMA remained negative pre-transplant. After twelve weeks of antiviral therapy, he developed elevated liver enzyme tests associated with an AMA seroconversion to seropositivity. A liver biopsy failed to show histological evidence of primary biliary cirrhosis or graft rejection. He was initiated on urseodeoxycholic acid with subsequent improvement of his liver enzymes. This case demonstrates that despite adequate immunosuppression, AMA seroconversion may occur post-transplant during interferon-based therapy. As AMA seroconversion did not occur during the pre-transplant PEG-IFN therapy, we speculate that donor allograft antigens in combination with PEG-IFN may have been a factor in the post-transplant seroconversion.
- Subjects
INTERFERONS; CHRONIC hepatitis C; LIVER transplantation; SEROCONVERSION; AUTOANTIBODIES; AUTOIMMUNE diseases
- Publication
Annals of Hepatology: Official Journal of the Mexican Association of Hepatology, 2014, Vol 13, Issue 5, p565
- ISSN
1665-2681
- Publication type
Article
- DOI
10.1016/s1665-2681(19)31258-x